When did Trump announce he was given monoclonal antibody therapy in 2020?

1. Timeline: when the announcement and treatment happened

Contemporaneous press coverage reported that President Trump tested positive and then received an infusion of Regeneron’s experimental antibody cocktail in early October 2020; outlets documenting the events published stories between October 5 and October 9, 2020 describing that he “received” the Regeneron therapy and that he and the White House publicly referenced it in the days after his diagnosis ^{[1] [2] [3]}.

2. What exactly was announced — and by whom

Reporting identified the product as Regeneron’s REGN‑COV2, a two‑antibody “cocktail,” and described Trump and White House communications as saying he had been given that monoclonal‑antibody treatment as part of his care; several outlets noted the president himself praised the therapy publicly afterwards ^{[1] [3] [4]}.

3. Regulatory context: experimental use and later EUA

At the time the president received the infusion the Regeneron cocktail was still investigational and being administered under special access (“compassionate use”); Regeneron and others were pursuing emergency use authorization, and the FDA later authorized Regeneron’s antibody therapy for certain outpatients on November 22, 2020 ^{[4] [5]}.

4. Medical framing and limits of the claim “it cured me”

Multiple outlets stressed that monoclonal antibodies were promising but not a proven “cure” based on a single case. Analysts and science writers noted early, unpublished or limited data suggested benefit in lowering viral load and possibly preventing progression — but warned Trump’s recovery could not definitively be attributed to the cocktail alone, since he received multiple treatments (remdesivir, dexamethasone and others) ^{[3] [4] [6]}.

5. Supply, equity and political implications highlighted by sources

Journalists and experts raised concerns that the president’s access via compassionate use spotlighted scarcity and distribution questions: at the time Regeneron had doses for a limited number of patients (reported as roughly 50,000) and wider access was constrained, prompting debate about prioritization and how public attention could affect supply decisions ^{[3] [4] [7]}.

6. How contemporaries described the dose and administration

Reporting specified the Regeneron product is an intravenous antibody combination; some pieces described the infusion’s size in lay terms (e.g., “an eight‑gram infusion” reported by The Guardian in context of his treatment), while others focused on the drug’s two‑antibody design and typical dosing regimen under later authorization ^{[2] [5]}.

7. Alternative viewpoints and open questions in the record

Sources present two competing perspectives: proponents and company statements emphasized antibody therapy’s promise and the administration’s investments in such drugs ^{[8] [4]}, while science writers and clinicians cautioned that the single high‑profile case did not prove efficacy and that clinical trials were necessary to establish benefit and safety ^{[3] [6]}. Available sources do not mention precise hour‑by‑hour timestamps of the announcement beyond the early‑October window; they also do not provide an official White House press release text within the supplied records (not found in current reporting).

8. Bottom line for readers

The record in these sources is clear that Trump’s receipt and public mention of Regeneron’s monoclonal‑antibody therapy occurred in the first week of October 2020; the therapy was experimental at the time, later gained FDA emergency authorization in late November 2020, and its promotion by the president sparked debate about evidence, access and political influence in therapeutic allocation ^{[1] [5] [4]}.